Anesthesia Exposure in Children: Practitioners Respond to the 2016 FDA Drug Safety Communication

Area of Science:

• Anesthesiology
• Neurodevelopmental Assessment
• Pediatric Medicine

Background:

• In December 2016, the US Food and Drug Administration (FDA) issued a drug safety communication regarding 11 anesthetic and sedative medications.
• Potential neurotoxic effects were identified for children under 3 years and women in the third trimester of pregnancy.

Purpose of the Study:

• To address the implications of the 2016 FDA drug safety communication on clinical practice.
• To explore responses to anesthesia exposure concerns in pediatric surgical and non-surgical procedures.

Main Methods:

• A panel discussion at the Pediatric Anesthesia Neurodevelopmental Assessment (PANDA) symposium featured experts from pediatric anesthesiology, obstetrics, and surgery.
• Panelists addressed the impact of FDA labeling changes on clinical practice, patient discussions, and procedural timing.
• Discussions included professional society guidelines and national meeting topics related to anesthesia safety.

Main Results:

• Panelists shared specialty-specific perspectives on adapting clinical practice following the FDA warning.
• The discussion highlighted the need for updated guidelines and communication strategies regarding anesthesia exposure.
• The FDA provided insights into the procedures leading to the drug safety warning.

Conclusions:

• The FDA safety communication necessitates a re-evaluation of anesthetic practices in vulnerable pediatric and pregnant populations.
• Multidisciplinary collaboration and clear guidelines are crucial for managing anesthesia exposure risks.
• Ongoing dialogue and research are essential to ensure patient safety in pediatric anesthesia.